FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer

January 23, 2020 FDA

FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection

Previous Article
FDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures
FDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures

FDA Announces Key Actions to Advance Development of Novel Coronavirus Medical Countermeasures

Next Article
FDA informs health care providers, facilities and patients about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical
FDA informs health care providers, facilities and patients about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical

FDA is issuing a safety communication informing health care providers, facilities and patients about cybers...